Cargando…

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

BACKGROUND: Currently, no effective treatments exist for non-small cell lung cancer (NSCLC) after failure of gefitinib therapy. Pre-clinical studies have demonstrated that gefitinib-resistant NSCLC cells are more sensitive to irinotecan than parental cells, and that combined administration of irinot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horiike, A, Kudo, K, Miyauchi, E, Ohyanagi, F, Kasahara, K, Horai, T, Nishio, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208500/ https://www.ncbi.nlm.nih.gov/pubmed/21915126 http://dx.doi.org/10.1038/bjc.2011.375

Ejemplares similares

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
por: Ohyanagi, F, et al.
Publicado: (2009)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
por: Nishio, M, et al.
Publicado: (2013)

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
por: Suzuki, R, et al.
Publicado: (2006)

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients
por: Lim, S-T, et al.
Publicado: (2005)

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
por: Cappuzzo, F, et al.
Publicado: (2005)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
por: Yano, Yukihiro, et al.
Publicado: (2012)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
por: Jackman, David M., et al.
Publicado: (2015)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
por: Veronese, M L, et al.
Publicado: (2005)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
por: Cappuzzo, F, et al.
Publicado: (2004)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
por: Sutani, A, et al.
Publicado: (2006)

A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer
por: Takeda, Y, et al.
Publicado: (2005)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer
por: Yu, Wanjun, et al.
Publicado: (2021)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
por: Stebbing, J, et al.
Publicado: (2008)

Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer
por: Wang, Jingjing, et al.
Publicado: (2016)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
por: Douillard, J-Y, et al.
Publicado: (2014)

Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t501bpo0gfpcmluj9paauc4p2c